Sunday, June 21, 2015 11:03:56 AM
Ouch. It was around midnight when I was hurrying to finish my post. I was going to proof read it but decided to wait until this morning. I should not have posted it, especially since I would not be able to correct any mistakes. I will proof read it now and then repost it. I can't believe that you are reading that entire write up, since you have probably read the original drafts. By your question, I suspect that I wrote Fisher, someone I know, instead of Frost. That is why I said ouch.
When I originally looked at OPK I realized that the drugs that the company was working on were special. Most companies just do some minor changes to a drug, and so they won't get a major share of the market for that drug. Other companies do make a major breakthrough, but they only have one drug that they are working on. We have multiple drugs with multiple breakthroughs. So the key to understanding our company is to understand the drugs that it is working on. So I tried to explain their significance in a way that anyone not with a medical background would be able to understand them. And, of course, another key to our company is Dr. Frost.
I will now look at what I wrote, correct it, and repost it.
When I originally looked at OPK I realized that the drugs that the company was working on were special. Most companies just do some minor changes to a drug, and so they won't get a major share of the market for that drug. Other companies do make a major breakthrough, but they only have one drug that they are working on. We have multiple drugs with multiple breakthroughs. So the key to understanding our company is to understand the drugs that it is working on. So I tried to explain their significance in a way that anyone not with a medical background would be able to understand them. And, of course, another key to our company is Dr. Frost.
I will now look at what I wrote, correct it, and repost it.
Recent OPK News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:04:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:01:43 PM
- OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:06:14 PM
- OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results • GlobeNewswire Inc. • 04/28/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
- OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 10/29/2025 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications • GlobeNewswire Inc. • 10/29/2025 12:00:00 PM
